Join the club for FREE to access the whole archive and other member benefits.


Company developing patient-specific immunotherapies for cancer.

At BioNTech we understand that every cancer patient’s tumor is unique and therefore each patient’s treatment should be individualized.

To pioneer the next generation of patient-specific immunotherapies, we have combined ground-breaking research with cutting-edge technologies to develop therapeutics for cancer and beyond. Our broad and synergistic suite of platforms, which include mRNA therapeutics, engineered cell therapies, antibodies and small molecule immunomodulators have been optimized for distinct modes of action, high precision targeting, high potency and efficacy. We are also developing in parallel our own state-of-the-art manufacturing processes to complement our drug development platforms.

Visit website:



People at BioNTech

Ozlem Tureci

Co-Founder and Chief Medical Officer of BioNTech

Ugur Sahin

Professor Medicine at University of Mainz and Co-Founder and CEO of BioNTech.

BioNTech News

BioNTech begins human trials for mRNA therapy targeting colon cancer and melanoma (LEAF) - 10-Sep-2021

mRNA cocktail treatment shows anti-tumor effect without toxic side effects in mice


Cancer vaccines based on mRNA technology will be available soon

Sky News - 19-Mar-2021

Science behind developing Covid-19 vaccines could bring us cancer shots too


BioNTech's vaccine prevents multiple sclerosis in rodents

FierceBiotech - 07-Jan-2021

Developed through a novel mRNA technology used in vaccine for COVID-19


Personalized cancer vaccines vanquish melanoma

Scientific American - 06-Jul-2017

Six melanoma patients given an experimental, custom-made, neoantigen vaccine. None of their tumo...


Could mRNA Overtake all other Biologicals in Medicine?

Labiotech - 05-Jan-2016

What if we could send the body an instruction to produce its own drug? RNA strand seems easier t...